CUE Cue Biopharma Inc

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.

During the fireside chat, Cue Biopharma will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers, as well as market opportunities, competitive positioning and anticipated milestones for 2024.

Presentation Details

JMP Securities Hematology and Oncology Summit

Date and Time: Tuesday, December 5, 11:30 a.m. EST

Webcast Link:

Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at . The webcast will be archived for 30 days.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit  and follow us on  and .

Investor Contact

Marie Campinell 

Senior Director, Corporate Communications

Cue Biopharma, Inc.

Media Contact

Maya Romanchuck

LifeSci Communications

 



EN
22/11/2023

Underlying

CUECue Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma to Present at the 2024 American Society of Clinical Onco...

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, April 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics,...

April 24, 2024 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Resu...

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights BOSTON, April 08, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. Presented additional positive data from the ongoing Phase 1 trials of CUE-101 in first line (1L) human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in combinatio...

April 8, 2024 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast BOSTON, April 02, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology progr...

April 2, 2024 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 20...

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating i...

February 29, 2024 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annu...

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024. During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the late...

February 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch